Tag: drug-coated balloons

paclitaxel

Meta-analysis finds a higher risk of death in the long term...

New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
paclitaxel

Without additional long-term and patient-level data, Katsanos et al’s conclusion is...

By Thomas Zeller The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...

Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB

After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable...

Particulate embolisation after femoral artery treatment with drug-coated balloons

Drug-eluting technologies, such as balloons coated with paclitaxel (DCB), are now the gold standard treatment for patients presenting with symptomatic peripheral artery disease (PAD) in the...

Global cohorts report drug-coated balloon success above the knee and “promising”...

Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...

Medtronic announces Health Canada licence for IN.PACT Admiral drug-coated balloon

Medtronic Canada, a subsidiary of Medtronic, has announced it has obtained Health Canada licence for the IN.PACT Admiral drug-coated balloon. IN.PACT Admiral is a primary...

Initial patients enrolled in first-in-man study of Selution sirolimus-coated balloon

Med Alliance has announced first patient enrolment in the first-in-man study of the Selution novel sirolimus-coated balloon. Patients were enrolled at the Universitaets-Herzzentrum, Bad...